From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Legal status
  • Uncontrolled
Routes of
CAS Registry Number 176975-26-1
ATC code None
PubChem CID: 172988
ChemSpider 151061
UNII A5E8C36F34 YesY
Chemical data
Formula C24H26N2OS2
Molecular mass 422.61 g/mol

Izonsteride (LY-320,236) is a selective inhibitor of the 5α-reductase, with dual effects on both the type I and type II isoforms of the enzyme.[1] It was under development by Eli Lilly and Company and Fujisawa for the treatment of benign prostatic hyperplasia but was never marketed.[2] Izonsteride may also be useful in the treatment of androgenic alopecia.[1]


The scheme used to produce a somewhat more complex 5-a-reductase inhibitor relies on a chiral auxiliary to yield the final product as a single enantiomer. The first step starts with the reaction of bromotetralone with R-α-phenethylamine to afford the enamine. Reaction with methyl iodide adds the methyl group at what will be a steroid-like AB ring junction.

Preparation of Izonsteride

This product is then treated with acryloyl chloride. The initial step in this case probably involves the acylation of nitrogen on the enamine; conjugate addition then completes the formation of the lactam ring. Treatment of that product with triethyl silane then reduces the ring unsaturation and cleaves the benzylic nitrogen bond on the auxiliary to yield as the optically pure trans isomer. Displacement of bromine with the mercapto benzthiazole completes the synthesis of izonsteride.[3]

See also[edit]


  1. ^ a b Chang, Chawnshang (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4. 
  2. ^ "Present and future pharmacotherapy for benign prostatic hyperplasia". 
  3. ^ Audia, J. R.; McQuaid, L. A.; Neubauer, B. L.; Rocco, V. P.; 1997, U.S. Patent 5,662,962.